Anatara Lifesciences Ltd
ANR
Company Profile
Business description
Anatara Lifesciences Ltd is developing and commercializing evidence-based products for gastrointestinal health where there is unmet need. It is focused on building a pipeline of human health products and has had a particular focus on conditions that involve the complexity of the gastrointestinal tract. The company operates in a single segment; that is, the research and development of oral solutions for gastrointestinal diseases and the commercialization of the Detach diarrhoea treatment for piglets.
Contact
c/- Perks, Level 8, 81 Flinders Street
AdelaideSA5000
AUST: +61 438027172
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
stocks
Our view after Coles’ shares plunge
Shares dropped 8% after reporting results for the September 2026 quarter.
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,981.00 | 3.80 | 0.04% |
| CAC 40 | 8,047.69 | 78.27 | 0.98% |
| DAX 40 | 25,981.09 | 162.88 | 0.63% |
| Dow JONES (US) | 51,983.98 | 213.67 | 0.41% |
| FTSE 100 | 10,761.33 | 31.55 | 0.29% |
| HKSE | 23,485.72 | 92.40 | 0.39% |
| NASDAQ | 25,164.31 | 272.68 | -1.07% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,699.12 | 0.49 | 0.00% |
| S&P 500 | 7,541.40 | 38.67 | -0.51% |
| S&P/ASX 200 | 8,859.60 | 3.10 | 0.04% |
| SSE Composite Index | 3,603.97 | 34.06 | -0.94% |